Differentiation of atrial fibrillation progression phenotypes using Troponin T.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 12 2019
Historique:
received: 27 05 2019
revised: 28 07 2019
accepted: 04 09 2019
pubmed: 16 9 2019
medline: 11 7 2020
entrez: 16 9 2019
Statut: ppublish

Résumé

Electro-anatomical remodeling in atrial fibrillation (AF) is associated with disease initiation and progression. Troponin T (TropT) - a specific biomarker for myocardial damage - is associated with AF incidence. However, its association with AF progression is understudied. The aim of the current analysis was to investigate the association between TropT and AF progression phenotypes: persistent AF and left atrial low voltage areas (LVAs). Patients undergoing first AF ablation were included into analyses. LVAs were determined using high-density maps and defined as <0.5 mV. Blood samples from femoral vein were collected before catheter ablation. The analysis of TropT serum concentrations was performed using a high-sensitive assay from Roche Diagnostics. Biomarkers, clinical, anthropometric and echocardiographic data were compared with healthy individuals from the epidemiological cohort. The study included 824 healthy individuals without overt cardiovascular disease (54 ± 10 years, 40% males) from epidemiological cohort and 241 AF patients (64 ± 11 years, 59% males, 59% persistent AF, 27% LVAs). Patients with AF had higher TropT levels and larger left atrium (LA), while healthy individuals had better renal function and ejection fraction (all p < 0.001). In clinical cohort, there were significant differences between TropT levels according to AF progression groups: paroxysmal AF without/with LVAs (n = 86/12), persistent AF without/with LVAs (n = 90/53): means 7.3, 12.9, 8.4, 11.3 pg/ml, p < 0.001, respectively. Similar findings were observed for LA and renal function (all p < 0.001). On ROC analysis, TropT significantly predicted LVAs (AUC 0.675, 95%CI 0.598-0.752, p < 0.001) in AF patients. TropT may be useful to differentiate AF progression phenotypes.

Sections du résumé

BACKGROUND
Electro-anatomical remodeling in atrial fibrillation (AF) is associated with disease initiation and progression. Troponin T (TropT) - a specific biomarker for myocardial damage - is associated with AF incidence. However, its association with AF progression is understudied. The aim of the current analysis was to investigate the association between TropT and AF progression phenotypes: persistent AF and left atrial low voltage areas (LVAs).
METHODS
Patients undergoing first AF ablation were included into analyses. LVAs were determined using high-density maps and defined as <0.5 mV. Blood samples from femoral vein were collected before catheter ablation. The analysis of TropT serum concentrations was performed using a high-sensitive assay from Roche Diagnostics. Biomarkers, clinical, anthropometric and echocardiographic data were compared with healthy individuals from the epidemiological cohort.
RESULTS
The study included 824 healthy individuals without overt cardiovascular disease (54 ± 10 years, 40% males) from epidemiological cohort and 241 AF patients (64 ± 11 years, 59% males, 59% persistent AF, 27% LVAs). Patients with AF had higher TropT levels and larger left atrium (LA), while healthy individuals had better renal function and ejection fraction (all p < 0.001). In clinical cohort, there were significant differences between TropT levels according to AF progression groups: paroxysmal AF without/with LVAs (n = 86/12), persistent AF without/with LVAs (n = 90/53): means 7.3, 12.9, 8.4, 11.3 pg/ml, p < 0.001, respectively. Similar findings were observed for LA and renal function (all p < 0.001). On ROC analysis, TropT significantly predicted LVAs (AUC 0.675, 95%CI 0.598-0.752, p < 0.001) in AF patients.
CONCLUSIONS
TropT may be useful to differentiate AF progression phenotypes.

Identifiants

pubmed: 31521439
pii: S0167-5273(19)32729-9
doi: 10.1016/j.ijcard.2019.09.006
pii:
doi:

Substances chimiques

Biomarkers 0
Troponin T 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-65

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Jelena Kornej (J)

Heart Center Leipzig at University of Leipzig, Leipzig, Germany; Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany. Electronic address: jelena.kornej@life.uni-leipzig.de.

Samira Zeynalova (S)

Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany.

Petra Büttner (P)

Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Ralph Burkhardt (R)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany.

Yoon Ju Bae (YJ)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany.

Anja Willenberg (A)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany.

Ronny Baber (R)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany.

Alexander Thaler (A)

Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Gerhard Hindricks (G)

Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Markus Loeffler (M)

Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany.

Andreas Hagendorff (A)

Department of Cardiology, University Clinic Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany.

Holger Thiele (H)

Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Joachim Thiery (J)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany; LIFE - Leipzig Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH